PTH(1-34) Treatment Increases Bisphosphonate Turnover in Fracture Repair in Rats.

Murphy CM, Schindeler A, Cantrill LC, Mikulec K, Peacock L, Little DG

Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research1 Jun 2015Cited by 22 (Europe PMC)

PMID25484198DOI10.1002/jbmr.2424PepBankPUB-25484198

Source link PubMedAsk about this study

Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. No result from this study comes from people.

01AnimalAnimal study (in vivo)Mechanism
In Wistar rats, PTH(1-34) reduced long-bone bisphosphonate fluorescence versus control, consistent with increased remobilization.
In plain wordsIn rats, PTH(1-34) reduced fluorescent bisphosphonate signals in long bones versus control.
Peptide
Teriparatide (PTH 1-34)
Outcome
DecreaseLong-bone bisphosphonate fluorescence
Study
ratn: not reported in source
Wistar normal growth and closed fracture repair
Comparator
Saline
Outcome group
Bone and joint · Musculoskeletal
Studied dose
25 μg/kg/dAs given in this study (rat).
Source sentences
Summary
Consistent with increased BP remobilization with PTH(1-34) , there was a significant decrease in fluorescence in both the long bones and in the fracture callus in treated animals compared with controls.
2 context sentences(design, population, supporting numbers)
Summary · context
These traceable BPs were dosed to Wistar rats in models of normal growth and closed fracture repair.
Summary · context
Rats were cotreated with saline or 25 μg/kg/d PTH(1-34) , and the effects on BP liberation and bone healing were examined by X-ray, micro-CT, autoradiography, and fluorescent confocal microscopy.
Report a problemFND-2548419801
02AnimalAnimal study (in vivo)Mechanism
In Wistar rats, PTH(1-34) reduced bisphosphonate fluorescence in fracture callus versus control.
In plain wordsIn rats, PTH(1-34) reduced fluorescent bisphosphonate signals at fracture repair sites versus control.
Peptide
Teriparatide (PTH 1-34)
Outcome
DecreaseFracture callus bisphosphonate fluorescence
Study
ratn: not reported in source
Wistar normal growth and closed fracture repair
Comparator
Saline
Outcome group
Bone and joint · Musculoskeletal
Studied dose
25 μg/kg/dAs given in this study (rat).
Source sentences
Summary
Consistent with increased BP remobilization with PTH(1-34) , there was a significant decrease in fluorescence in both the long bones and in the fracture callus in treated animals compared with controls.
2 context sentences(design, population, supporting numbers)
Summary · context
These traceable BPs were dosed to Wistar rats in models of normal growth and closed fracture repair.
Summary · context
Rats were cotreated with saline or 25 μg/kg/d PTH(1-34) , and the effects on BP liberation and bone healing were examined by X-ray, micro-CT, autoradiography, and fluorescent confocal microscopy.
Report a problemFND-2548419802
03AnimalAnimal study (in vivo)Mechanism
In Wistar rats, autoradiography confirmed increased bisphosphonate remobilization with PTH(1-34) versus control.
In plain wordsIn rats, radioactive imaging confirmed that PTH(1-34) increased bisphosphonate remobilization versus control.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseRadiolabeled zoledronic acid remobilization
Study
ratn: not reported in source
Wistar normal growth and closed fracture repair
Comparator
Saline
Outcome group
Bone and joint · Musculoskeletal
Studied dose
25 μg/kg/dAs given in this study (rat).
Source sentences
Summary
Consistent with increased BP remobilization with PTH(1-34) , there was a significant decrease in fluorescence in both the long bones and in the fracture callus in treated animals compared with controls. This was further confirmed by autoradiography for (14) C-ZA.
2 context sentences(design, population, supporting numbers)
Summary · context
These traceable BPs were dosed to Wistar rats in models of normal growth and closed fracture repair.
Summary · context
Rats were cotreated with saline or 25 μg/kg/d PTH(1-34) , and the effects on BP liberation and bone healing were examined by X-ray, micro-CT, autoradiography, and fluorescent confocal microscopy.
Report a problemFND-2548419803
04AnimalAnimal study (in vivo)Efficacy outcome
In rats receiving acute bisphosphonate treatment, PTH(1-34) did not alter callus bone volume despite reducing callus-bound bisphosphonate.
In plain wordsIn rats receiving bisphosphonates, PTH(1-34) did not change repair-site bone volume versus control.
Peptide
Teriparatide (PTH 1-34)
Outcome
No significant changeCallus bone volume
Study
ratn: not reported in source
Wistar normal growth and closed fracture repair
Comparator
Saline
Outcome group
Bone and joint · Musculoskeletal
Studied dose
25 μg/kg/dAs given in this study (rat).
Source sentences
Summary
In this model of acute BP treatment, callus bone volume (BV) was significantly increased in fractured limbs, and although we noted significant decreases in callus-bound BP with PTH(1-34) , these were not sufficient to alter this BV.
2 context sentences(design, population, supporting numbers)
Summary · context
These traceable BPs were dosed to Wistar rats in models of normal growth and closed fracture repair.
Summary · context
Rats were cotreated with saline or 25 μg/kg/d PTH(1-34) , and the effects on BP liberation and bone healing were examined by X-ray, micro-CT, autoradiography, and fluorescent confocal microscopy.
Report a problemFND-2548419804
05AnimalAnimal study (in vivo)Mechanism
In rats receiving acute bisphosphonate treatment, PTH(1-34) significantly reduced callus-bound bisphosphonate versus control.
In plain wordsIn rats receiving bisphosphonates, PTH(1-34) reduced bisphosphonate bound at fracture repair sites versus control.
Peptide
Teriparatide (PTH 1-34)
Outcome
DecreaseCallus-bound bisphosphonate
Study
ratn: not reported in source
Wistar normal growth and closed fracture repair
Comparator
Saline
Outcome group
Bone and joint · Musculoskeletal
Studied dose
25 μg/kg/dAs given in this study (rat).
Source sentences
Summary
In this model of acute BP treatment, callus bone volume (BV) was significantly increased in fractured limbs, and although we noted significant decreases in callus-bound BP with PTH(1-34) , these were not sufficient to alter this BV.
2 context sentences(design, population, supporting numbers)
Summary · context
These traceable BPs were dosed to Wistar rats in models of normal growth and closed fracture repair.
Summary · context
Rats were cotreated with saline or 25 μg/kg/d PTH(1-34) , and the effects on BP liberation and bone healing were examined by X-ray, micro-CT, autoradiography, and fluorescent confocal microscopy.
Report a problemFND-2548419805
06AnimalAnimal study (in vivo)Mechanism
In Wistar rats, PTH(1-34) increased intracellular bisphosphonate in resorbing osteoclasts.
In plain wordsIn rats, PTH(1-34) increased bisphosphonate inside bone-resorbing cells versus control.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseIntracellular bisphosphonate in osteoclasts
Study
ratn: not reported in source
Wistar normal growth and closed fracture repair
Comparator
Saline
Outcome group
Bone and joint · Musculoskeletal
Studied dose
25 μg/kg/dAs given in this study (rat).
Source sentences
Summary
However, increased intracellular BP was noted in resorbing osteoclasts, confirming that, in principle, PTH(1-34) increases bone turnover as well as BP turnover.
2 context sentences(design, population, supporting numbers)
Summary · context
These traceable BPs were dosed to Wistar rats in models of normal growth and closed fracture repair.
Summary · context
Rats were cotreated with saline or 25 μg/kg/d PTH(1-34) , and the effects on BP liberation and bone healing were examined by X-ray, micro-CT, autoradiography, and fluorescent confocal microscopy.
Report a problemFND-2548419806

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.